September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
High dose (2.5 mg) intravitreal bevacizumab as rescue therapy for persistent post-radiation cystoid macular edema
Author Affiliations & Notes
  • M. Ali Khan
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Arman Mashayekhi
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Kyle Ferguson
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Jerry A Shields
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Carol L Shields
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   M. Ali Khan, None; Arman Mashayekhi, None; Kyle Ferguson, None; Jerry Shields, None; Carol Shields, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4099. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      M. Ali Khan, Arman Mashayekhi, Kyle Ferguson, Jerry A Shields, Carol L Shields; High dose (2.5 mg) intravitreal bevacizumab as rescue therapy for persistent post-radiation cystoid macular edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4099.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the efficacy of intravitreal high dose (2.5 mg) bevacizumab as rescue therapy for post-radiation cystoid macular edema (CME) resistant to standard dose (1.25 mg) bevacizumab.

Methods : Retrospective, interventional case series at Wills Eye Hospital (Philadelphia, PA).

Results : Fifteen eyes of 15 patients were included. All eyes were treated with a mean of 10 standard-dose (1.25 mg) bevacizumab injections but failed to show complete CME resolution. Following 3 monthly treatments of high dose (2.5 mg) bevacizumab, mean CMT reduced significantly from 406±100 to 360±83 microns (p = 0.013) and mean VA improved from 0.55±0.17 (Snellen 20/71) to 0.48±0.21 (Snellen 20/60, p = 0.07). At mean final follow-up of 9 months, CMT was 395±124 (p=0.67) and VA was 0.51±0.23 (Snellen 20/65, p=0.22) following a mean of 7.5 high dose (2.5 mg) bevacizumab treatments. Five eyes (30%) had a >10% reduction in CMT at final follow-up. In these eyes, the observed reduction in CMT was statistically significant (p=0.04) and logMAR visual acuity was significantly better (p=<0.01) compared to the remainder of the cohort.

Conclusions : High dose (2.5 mg) intravitreal bevacizumab resulted in a significant improvement in CMT and VA outcomes in a subset of eyes (5/15, 30%) following incomplete response to standard dose (1.25 mg) bevacizumab. Our results indicate more work is necessary to explore rescue therapies in this patient population.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×